Status:

NOT_YET_RECRUITING

An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines

Lead Sponsor:

Qualia Life Sciences

Conditions:

Inflammation

Eligibility:

All Genders

45-79 years

Phase:

NA

Brief Summary

This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline...

Detailed Description

Objectives Within-group changes in outcomes will be compared from baseline to the end of the study period. Primary Outcome Measures: Biomarkers in blood, measured using the Olink Target 48 Cytokine ...

Eligibility Criteria

Inclusion

  • Provide voluntary, written, informed consent to participate in the study
  • Agree to provide a valid cell phone number and are willing to receive communications through text.
  • Healthy adults 45 - 79 years of age Can read and write English
  • Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly.
  • Willing to self-administer the fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives NHC access to the results of these tests.
  • Willing to complete questionnaires, records, and diaries associated with the study.

Exclusion

  • Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
  • Known food intolerances/allergy to any ingredients in the product
  • Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer
  • Having had a significant cardiovascular event in the past 6 months
  • Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
  • On immunosuppressive therapy
  • Individuals who were deemed incompatible with the test protocol
  • Adults lacking capacity to consent

Key Trial Info

Start Date :

May 12 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 18 2025

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT06953518

Start Date

May 12 2025

End Date

May 18 2025

Last Update

May 1 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Qualia Life Sciences

Carlsbad, California, United States, 92011

An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines | DecenTrialz